<DOC>
	<DOCNO>NCT01561963</DOCNO>
	<brief_summary>The purpose study evaluate pharmacokinetics apremilast may affect single intravenous dose rifampin multiple oral dos rifampin .</brief_summary>
	<brief_title>A Drug-Drug Interaction Study Evaluate Effect Rifampin Pharmacokinetics Apremilast</brief_title>
	<detailed_description />
	<mesh_term>Rifampin</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Apremilast</mesh_term>
	<criteria>Healthy male female subject ethnic origin age 18 55 body mass index 18 33 Recent history ( i.e. , within 3 year ) clinically significant neurological , gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , endocrine , hematological , dermatological , psychological , allergic major disorder . Use prescribed nonprescribed systemic topical medication ( include vitamin herbal medicine , e.g . St. John 's Wort ) within 30 day first dose , unless exception grant sponsor . Presence surgical medical condition possibly affect drug absorption , distribution , metabolism , excretion , plan elective medical procedure conduct trial . Exposure investigational drug ( new chemical entity ) within 30 day prior first dose administration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Apremilast</keyword>
	<keyword>drug interaction</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>